Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates.
The minimum inhibitory concentration (MIC) and postantibiotic effect (PAE) of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin were evaluated in vitro against 43 feline-source Bordetella bronchiseptica strains. All strains tested were susceptible to marbofloxacin and enrofloxacin (MIC90 0.5mg/l), while 93 and 84% of the strains were susceptible, respectively, to ciprofloxacin and difloxacin with MIC(90) values of, respectively, 1 and 8mg/l. The PAE was studied in 10 strains by exposure of bacteria to marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin at 5 and 10 times minimum inhibitory concentration (MIC) for 1 and 2h. Regrowth was determined by measuring the viable counts after drug removal by a 10(3) dilution procedure. PAEs increased as a function of concentration and exposure time. The mean duration of PAEs varied between 1.1 and 8.2h, showing the following order: marbofloxacin>enrofloxacin>ciprofloxacin>difloxacin. These data are encouraging since fluoroquinolones have a possible role in the clinical treatment of B. bronchiseptica infections, and the strong PAE caused by quinolones may contribute to the in vivo efficacy of these drugs.
Carbone
M
M
Istituto di Microbiologia, Facoltà di Medicina e Chirurgia, Policlinico Universitario, Torre Biologica, 2 degrees piano, Università di Messina, 98125, Messina, Italy. mtfera@www.unime.it
Pennisi
M G
MG
Masucci
M
M
De Sarro
A
A
Giannone
M
M
Fera
M T
MT
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001885:Bordetella Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D016950:Bordetella bronchiseptica / Q000187:drug effects*; D002371:Cat Diseases / Q000188:drug therapy / Q000382:microbiology; D002415:Cats; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones; D008297:Male; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin; C047225:difloxacin; C080260:marbofloxacin